Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NOVA-BCL6-1, A First-in-Human, Multicenter Phase 1a/1b Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of LY4584180 in Adult Participants With Previously Treated Hematologic Malignancies

NCT07226843 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT07226843
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07226843 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NOVA-BCL6-1, A First-in-Human, Multicenter Phase 1a/1b Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of LY4584180 in Adult Participants With Previously Treated Hematologic Malignancies
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Recruiting
Start date
April 17, 2026
Completion date
February 28, 2030
Enrollment
460 (estimated)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma, lymphoma, diffuse large b-cell, lymphoma, non-hodgkin's